Celcuity Inc. CELC

US Biotechnology

$69.23 ▼ -1.62% ($-1.14)

🔥 High Short Interest

Open $69.24

Prev Close $70.37

Day Range $68.96 – $71.01

52W Range $53.54 – $151.02

Market Cap $3.27B

Beta 0.19

EPS (TTM) $-4.30

📋 Company Profile

Industry	Biotechnology
Country	US
Exchange	NASDAQ NMS - GLOBAL MARKET
Currency	USD
IPO Date	2017-09-20
Shares Out.	48,930,000
Website	celcuity.com/ ↗
Phone	13026587581
Employees	155
Revenue	$0
Gross Profit	$0
Net Income	-$78.9M
Free Cash Flow	-$192.2M
Total Assets	$828.2M
Total Liabilities	$841.0M
Equity	-$12.8M

About Celcuity Inc.

Celcuity Inc is a clinical-stage biotechnology company developing targeted therapies for multiple solid tumors. Its candidate, gedatolisib, is a kinase inhibitor of the PI3K/AKT/mTOR (PAM) pathway, binding all class I PI3K isoforms and mTORC1/2, offering comprehensive inhibition with a mechanism and pharmacokinetics differentiated from other therapies. The Phase 3 VIKTORIA-1 trial, evaluating gedatolisib with fulvestrant, with or without palbociclib, in HR+/HER2- breast cancer, has completed enrollment and reported results for PIK3CA WT tumors, with cohort 2 (PIK3CA MT) also enrolled. Phase 3 VIKTORIA-2 and Phase 1b/2 CELC-G-201 trials, evaluating combinations in endocrine-resistant HR+/HER2- breast cancer and metastatic castration-resistant prostate cancer, are ongoing.

Celcuity Inc. is a publicly traded company under the ticker symbol CELC on the NASDAQ NMS - GLOBAL MARKET, operating in the Biotechnology industry. Quotes and metrics shown here are sourced from public market data and refreshed regularly.